

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Pfizer Inc.

Application No./Patent No.: 7,163,693 Filed/Issue Date: January 16, 2007

Titled: Multi-Component Pharmaceutical Dosage Form

Pfizer Inc. , a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest in;
2. an assignee of less than the entire right, title, and interest in
(The extent (by percentage) of its ownership interest is _____ %); or
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made) the patent application/patent identified above, by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy therefore is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Allan Clarke, Teodoro Fonio, Goeffrey Harris To: SmithKline Beecham p.l.c.
The document was recorded in the United States Patent and Trademark Office at
Reel 013309, Frame 0662, or for which a copy thereof is attached.

2. From: SmithKline Beecham p.l.c. To: SmithKline Beecham Limited
The document was recorded in the United States Patent and Trademark Office at
Reel 026072, Frame 0808, or for which a copy thereof is attached.

3. From: SmithKline Beecham Limited To: Pfizer Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 025877, Frame 0349, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet(s).

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Gregg C. Benson

Printed or Typed Name

Title

Date

VP & Asst. General Counsel

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Chain of Title Supplemental Sheet page 2 of 2

Application No./Patent No.: 7,163,693 Filed/Issue Date: January 16, 2007

Entitled: "Multi-Component Pharmaceutical Dosage Form"

A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Ron Kift, Donald Lightfoot, Shane McGinley, Thomas Ofsharick, Margaret M. Szymczak To: SmithKline Beechman p.l.c.

The document was recorded in the United States Patent and Trademark Office at Reel 013309, Frame 0662, or for which a copy thereof is attached.

4. From: SmithKline Beecham Limited To: Pfizer Inc.

The document was recorded in the United States Patent and Trademark Office at Reel 026169, Frame 0043, or for which a copy thereof is attached.